
Proceedings Paper
Defining a therapeutic dosage window for transmeatal-LLLT applied to the rats with NIHL to Ameliorate NIHLFormat | Member Price | Non-Member Price |
---|---|---|
$17.00 | $21.00 |
Paper Abstract
Aim: The LLLT was found to recover NIHL and ototoxicity induced hearing loss in rats but the optimal LLLT laser
dosage to treat NIHL needs to be determined. The aim of this study was to find the optimal laser dosage to recover a
NIHL with transmeatal-LLLT. Methods: Bilateral ears of rats were exposed to noise (narrow band noise, 120 dB, 16
kHz, 6 h). Left ears of the rats were irradiated with transmeatal-LLLT (830 nm) of 50, 100, 150, 200, 250, 300 mW for
60 minutes per day for 12 days, starting 1 day post induction of NIHL. Right ears were not irradiated and used as control
ears. The hearing levels were measured at each frequency of 8, 12, and 32 kHz before the noise exposure, 1, 3, 8, and 12
days post noise exposure. The differences of hearing levels between left treated ear and right controlled ear at each
frequency of different laser dosages (50 – 300 mW) were compared to see the most effective laser dosages to treat NIHL.
Results: Hearing levels were most improved by 150 mW, slightly improved by 200 mW, not improved by 50 and 250
mW, and became worse by 300 mW. Conclusion: The results of this study suggest that most effective therapeutic laser
dosage window to treat NIHL with transmeatal-LLLT was 150 mW for 12 days and it was not effective by 50, 250, and
300 mW.
Paper Details
Date Published: 26 February 2015
PDF: 6 pages
Proc. SPIE 9303, Photonic Therapeutics and Diagnostics XI, 93031M (26 February 2015); doi: 10.1117/12.2083044
Published in SPIE Proceedings Vol. 9303:
Photonic Therapeutics and Diagnostics XI
Hyun Wook Kang; Brian J. F. Wong M.D.; Melissa C. Skala; Bernard Choi; Guillermo J. Tearney M.D.; Andreas Mandelis; Nikiforos Kollias; Kenton W. Gregory M.D.; Mark W. Dewhirst D.V.M.; Justus F. Ilgner M.D.; Alfred Nuttal; Haishan Zeng; Laura Marcu; Claus-Peter Richter, Editor(s)
PDF: 6 pages
Proc. SPIE 9303, Photonic Therapeutics and Diagnostics XI, 93031M (26 February 2015); doi: 10.1117/12.2083044
Show Author Affiliations
ChungKu Rhee M.D., Dankook Univ. Hospital (Korea, Republic of)
Kevin Song, Univ. of Illinois at Champaign-Urbana (United States)
So-Young Chang, Dankook Univ. Hospital (Korea, Republic of)
Jae Yun Jung, Dankook Univ. Hospital (Korea, Republic of)
Kevin Song, Univ. of Illinois at Champaign-Urbana (United States)
So-Young Chang, Dankook Univ. Hospital (Korea, Republic of)
Jae Yun Jung, Dankook Univ. Hospital (Korea, Republic of)
Sung-Kyoo Lim, Dankook Univ. Hospital (Korea, Republic of)
Phil-Sang Chung M.D., Dankook Univ. Hospital (Korea, Republic of)
Myung-Whan Suh M.D., Seoul National Univ. (Korea, Republic of)
Phil-Sang Chung M.D., Dankook Univ. Hospital (Korea, Republic of)
Myung-Whan Suh M.D., Seoul National Univ. (Korea, Republic of)
Published in SPIE Proceedings Vol. 9303:
Photonic Therapeutics and Diagnostics XI
Hyun Wook Kang; Brian J. F. Wong M.D.; Melissa C. Skala; Bernard Choi; Guillermo J. Tearney M.D.; Andreas Mandelis; Nikiforos Kollias; Kenton W. Gregory M.D.; Mark W. Dewhirst D.V.M.; Justus F. Ilgner M.D.; Alfred Nuttal; Haishan Zeng; Laura Marcu; Claus-Peter Richter, Editor(s)
© SPIE. Terms of Use
